Overview

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The patients are being asked to take part in this study because they have a hormone receptor-positive breast cancer (contains estrogen and/or progesterone receptors) and their doctor has told them that they have an option to receive chemotherapy or hormonal therapy before surgery. The purpose of this study is to assess if chemotherapy using docetaxel and cytoxan (TC) or hormonal therapy using exemestane can shrink the size of their breast tumor and allow them to preserve the breast or have less extensive surgery on their breast.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborator:
Pfizer
Treatments:
Cyclophosphamide
Docetaxel
Exemestane